Ingenol mebutate‐mediated reduction in p53‐positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses

2019 ◽  
Vol 33 (7) ◽  
pp. 1297-1303 ◽  
Author(s):  
V. Grandi ◽  
P. Gennaro ◽  
S. Torrigiani ◽  
L. Basco ◽  
I. Lastrucci ◽  
...  
Keyword(s):  
Clinical Response ◽  
Ingenol Mebutate ◽  
Actinic Keratoses ◽  
Cancerization Field ◽  
Mediated Reduction

scholarly journals Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives

2019 ◽  
Vol 94 (3) ◽  
pp. 313-319
Author(s):  
Luiz Gameiro ◽  
Luis Fernando Requejo Tovo ◽  
José Antonio Sanches Júnior ◽  
Ivan Aprahamian
Keyword(s):  
Ingenol Mebutate ◽  
Actinic Keratoses ◽  
The Face ◽  
Cancerization Field

scholarly journals Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses

2015 ◽  
Vol 106 (10) ◽  
pp. e55-e61
Author(s):  
A. Batalla ◽  
Á. Flórez ◽  
C. Feal ◽  
G. Peón ◽  
M.T. Abalde ◽  
...  
Keyword(s):  
Clinical Response ◽  
Ingenol Mebutate ◽  
Actinic Keratoses

Do Second-Time Users of Topical Imiquimod have a More Rapid Onset of Clinical Response?

2018 ◽  
Vol 2 (3) ◽  
pp. 156-161
Author(s):  
Stacy L McMurray ◽  
Matthew Reynolds ◽  
Matthew S Dinehart ◽  
Scott M Dinehart
Keyword(s):  
Clinical Response ◽  
Time Use ◽  
Γδ T Cells ◽  
Rapid Onset ◽  
Primary Objective ◽  
Imiquimod Cream ◽  
Actinic Keratoses ◽  
Topical Imiquimod ◽  
Primary Endpoints ◽  
Time To Onset

Introduction: Topical imiquimod is commonly used in dermatology for treatment of actinic keratoses (AK). Prior studies in humans and mice have suggested the potential for immune recall with imiquimod based on higher degrees of AK clearance and activation of memory γδ T-cells in a mouse model. Anecdotal reports suggest a more rapid time-to-onset of clinical response with second time use of imiquimod. However, the potential for immune recall demonstrated by time-to-onset of clinical response has not been formally investigated.Objective:  The primary objective of this study was to determine if there is a difference in time-to-onset of clinical response between naïve and prior users of topical imiquimod for the treatment of actinic keratoses.Methods:  A total of 92 patients were treated with 5% imiquimod cream for actinic keratoses of the head and neck. Patients were instructed to apply 5% imiquimod cream to the affected areas once daily until reaching a therapeutic endpoint of crusting/scabbing. The primary endpoints in the study were time (days) to onset of erythema and time to onset of crusting/scabbing. Results were self-reported.Results:  The average time (days) to onset of erythema was 5.48 ± 3.19 days in naïve users and 4.7 ± 2.91 days in prior users (p= 0.22). Average time to onset of crusting/scabbing was 9.2 ± 4.34 days in naïve users and 9.02 ± 3.65 days in prior users (p=0.35).Conclusion:  Our study revealed there is no difference in time-to-onset of erythema or scabbing/crusting with second-time use of imiquimod.  While immune recall may be possible with use of imiquimod, the results of this study indicate that it may be independent of time-to-onset of clinical response.  

Erosive pustular dermatosis of the scalp following topical ingenol mebutate for actinic keratoses

2017 ◽  
Vol 30 (5) ◽  
pp. e12521 ◽  
Author(s):  
Mario Vaccaro ◽  
Francesco Borgia ◽  
Lorenzo Gasco ◽  
Serafinella P. Cannavò
Keyword(s):  
Ingenol Mebutate ◽  
Actinic Keratoses

Rapidly-growing squamous cell carcinoma shortly after treatment with ingenol mebutate for actinic keratoses: report of two cases

2015 ◽  
Vol 173 (6) ◽  
pp. 1514-1517 ◽  
Author(s):  
J.A. Moreno Romero ◽  
A. Campoy ◽  
N. Perez ◽  
F. Garcia ◽  
R. Grimalt
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Ingenol Mebutate ◽  
Actinic Keratoses
Sign in / Sign up

Export Citation Format

Share Document